APLS240816P35000
- 2.47
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Express News | Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Baird Initiates Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $100
Apellis Pharmaceuticals Strengthened Market Position and Buy Rating Following Competitor's Clinical Failure
Stifel Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $84
Apellis Pharmaceuticals (APLS) Receives a Buy From Stifel Nicolaus
Citi Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $60
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $46
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)
Buy Rating Affirmed on Apellis Pharmaceuticals Amid Promising Pegcetacoplan Trials and Expert Optimism
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $80
Jefferies Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
Express News | Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $77
Apellis Pharmaceuticals (NASDAQ:APLS) Shareholders Are up 9.8% This Past Week, but Still in the Red Over the Last Year
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH) and Apellis Pharmaceuticals (APLS)
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $49